193 related articles for article (PubMed ID: 16230887)
21. Val-HeFT: do angiotensin-receptor blockers benefit heart failure patients already receiving ACE inhibitor therapy?
McMurray JJ
Nat Clin Pract Cardiovasc Med; 2005 Mar; 2(3):128-9. PubMed ID: 16265452
[No Abstract] [Full Text] [Related]
22. Angiotensin antagonism in patients with heart failure: ACE inhibitors, angiotensin receptor antagonists or both?
Cruden NL; Newby DE
Am J Cardiovasc Drugs; 2004; 4(6):345-53. PubMed ID: 15554719
[TBL] [Abstract][Full Text] [Related]
23. New competition in the realm of renin-angiotensin axis inhibition; the angiotensin II receptor antagonists in congestive heart failure.
Martineau P; Goulet J
Ann Pharmacother; 2001 Jan; 35(1):71-84. PubMed ID: 11197588
[TBL] [Abstract][Full Text] [Related]
24. Clinical experience with angiotensin receptor blockers with particular reference to valsartan.
Chrysant SG; Chrysant GS
J Clin Hypertens (Greenwich); 2004 Aug; 6(8):445-51. PubMed ID: 15308883
[TBL] [Abstract][Full Text] [Related]
25. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
Jorde UP
Cardiol Rev; 2006; 14(2):81-7. PubMed ID: 16493245
[TBL] [Abstract][Full Text] [Related]
26. [Effects of long term therapy with angiotensin converting enzyme inhibitor quinapril, antagonist of receptors to angiotensin II valsartan, and combination of quinapril and valsartan in patients with moderate chronic heart failure. Main results of the SADKO-CHF study].
Skvortsov AA; Nasonova SN; Sychev AV; Orlova IaA; Baklanova NA; Masenko VP; Mareev VIu; Belenkov IuN
Kardiologiia; 2006; 46(7):33-51. PubMed ID: 16883264
[TBL] [Abstract][Full Text] [Related]
27. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
[TBL] [Abstract][Full Text] [Related]
28. The place of ARBs in heart failure therapy: is aldosterone suppression the key?
Markan U; Pasupuleti S; Pollard CM; Perez A; Aukszi B; Lymperopoulos A
Ther Adv Cardiovasc Dis; 2019; 13():1753944719868134. PubMed ID: 31401939
[TBL] [Abstract][Full Text] [Related]
29. Angiotensin receptor blockers for chronic heart failure and acute myocardial infarction.
McMurray JJ
Heart; 2001 Jul; 86(1):97-103. PubMed ID: 11410575
[No Abstract] [Full Text] [Related]
30. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions.
Burchill LJ; Velkoska E; Dean RG; Griggs K; Patel SK; Burrell LM
Clin Sci (Lond); 2012 Dec; 123(11):649-58. PubMed ID: 22715807
[TBL] [Abstract][Full Text] [Related]
31. [Angiotensin receptor blockers in heart failure. CHARM Study].
Kochsiek K
Internist (Berl); 2004 Sep; 45(9):1063-7. PubMed ID: 15309315
[No Abstract] [Full Text] [Related]
32. [Pharmocological therapeutics for chronic heart failure--how to use ARB (angiotensin receptor blocker].
Kudo Y; Komuro I; Akazawa H
Nihon Rinsho; 2007 May; 65 Suppl 5():84-9. PubMed ID: 17571370
[No Abstract] [Full Text] [Related]
33. [Angiotensin II receptor blockers: current status and future prospects].
Corvol P; Plouin PF
Drugs; 2002; 62 Spec No 1():53-64. PubMed ID: 12036389
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic trials comparing angiotensin converting enzyme inhibitors and angiotensin II receptor blockers.
Elliott WJ
Curr Hypertens Rep; 2000 Aug; 2(4):402-11. PubMed ID: 10981176
[TBL] [Abstract][Full Text] [Related]
35. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: what we know and current controversies.
Moser DK; Biddle MJ
Crit Care Nurs Clin North Am; 2003 Dec; 15(4):423-37, vii-viii. PubMed ID: 14717387
[TBL] [Abstract][Full Text] [Related]
36. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group.
Baruch L; Anand I; Cohen IS; Ziesche S; Judd D; Cohn JN
Circulation; 1999 May; 99(20):2658-64. PubMed ID: 10338459
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic potential of angiotensin receptor blockers in hypertension.
Cheung BM
Expert Opin Investig Drugs; 2006 Jun; 15(6):625-35. PubMed ID: 16732715
[TBL] [Abstract][Full Text] [Related]
38. Valsartan in chronic heart failure.
Ripley TL
Ann Pharmacother; 2005 Mar; 39(3):460-9. PubMed ID: 15687480
[TBL] [Abstract][Full Text] [Related]
39. Multiple renin-angiotensin-aldosterone-blocking agents in heart failure: how much is too much?
Pitt B
Curr Heart Fail Rep; 2009 Jun; 6(2):112-6. PubMed ID: 19486595
[TBL] [Abstract][Full Text] [Related]
40. Anti-angiotensin therapy: new perspectives.
Ramasubbu K; Mann DL; Deswal A
Cardiol Clin; 2007 Nov; 25(4):573-80; vi-vii. PubMed ID: 18063161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
